Life expectancy estimation in older men using the prostate cancer comorbidity index in VA & SEER-Medicare cohorts
Age and Ageing · 04.04.2026 · 55 (4)
DOI: 10.1093/ageing/afag097 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Age and Ageing, online erschienen am 27.04.2026. Verfasst von John Heard und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cedars-Sinai Medical Center - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Life Expectancy, Prostatic Neoplasms. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Guidelines endorse specific life expectancy (LE) cutoffs for triage of definitive local treatment of prostate cancer, but the lack of validated, prostate cancer-specific LE prediction tools limits incorporation of LE in management decisions.
Objective
We sought to provide long-term LE predictions in older men using the Prostate Cancer Comorbidity Index (PCCI), a validated tool for prediction of other-cause mortality based on age and presence and severity of major comorbidities, in nationally representative cohorts of US prostate cancer patients. Design, Setting, Subjects We performed an observational study of 916,890 men in the SEER-Medicare database and 243,928 men in the VA diagnosed with clinically localized prostate cancer between 2000 and 2019.
Methods
PCCI scores were calculated using ICD-9 and ICD-10 codes. Kaplan Meier and multivariable Cox proportional hazards analysis were used to measure overall survival by age-adjusted PCCI score groups.
Results
Median follow up was 11 years in both cohorts. In SEER-Medicare, men with PCCI scores of 1–2, 3–4, 5–6, 7–9, and 10+ had median estimated LE (95%CI) of 16.6 (16.5–16.7), 12.2 (12.1–12.2), 10.7 (10.6–10.7), 9.3 (9.2–9.3), and 5.4 (5.3–5.4) years, respectively. In the VA, men with the same PCCI scores had estimated median LE (95%CI) of 16.1 (16.0–16.3), 11.2 (11.1–11.4), 9.1 (8.9–9.2), 7.5 (7.4–7.7), and 5.2 (5.0–5.3) years, respectively.
Conclusions
The PCCI robustly predicts long-term longevity in SEER-Medicare and VA populations, with similar LE estimates in each. LE prediction tables with their accompanying variability estimates can help clinicians implement guidelines endorsed LE cutoffs for management of older men with prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cedars-Sinai Medical Center - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Cedars-Sinai Medical Center - Department of Biostatistics, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Stanford University - Department of Urology, Stanford University, Stanford, California, USA.
ORCID-Profile: John Heard, Michael Luu
Zitieren
APA
Heard, J., Luu, M., Thomas, I. C., Leppert, J., & Daskivich, T. (2026). Life expectancy estimation in older men using the prostate cancer comorbidity index in VA & SEER-Medicare cohorts. Age and Ageing, 55(4). https://doi.org/10.1093/ageing/afag097
Vancouver
Heard J, Luu M, Thomas IC, Leppert J, Daskivich T. Life expectancy estimation in older men using the prostate cancer comorbidity index in VA & SEER-Medicare cohorts. Age and Ageing. 2026;55(4). doi:10.1093/ageing/afag097
BibTeX
@article{Heard2026,
author = {Heard, John and Luu, Michael and Thomas, I-Chun and Leppert, John and Daskivich, Timothy},
title = {Life expectancy estimation in older men using the prostate cancer comorbidity index in VA & SEER-Medicare cohorts},
journal = {Age and Ageing},
year = {2026},
volume = {55},
number = {4},
doi = {10.1093/ageing/afag097}
}
EUVIMED